Cognoa Advocates for Expanded Insurance Coverage of Canvas Dx as CDC Reports 1 in 31 Children Now Identified with Autism

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

Recent CDC data reveals significant regional disparities in autism identification, highlighting the need for standardized, accessible diagnostic approaches nationwide.

PALO ALTO, Calif., April 17, 2025 /PRNewswire/ — In response to yesterday’s Centers for Disease Control and Prevention (CDC) report revealing that autism spectrum disorder now affects 1 in 31 U.S. children, Cognoa is calling for expanded insurance coverage of evidence-based diagnostic tools to address significant nationwide disparities in timely autism identification. 

The CDC’s latest data highlights substantial regional variations in autism diagnosis rates, ranging from 1 in 19 children in California to 1 in 103 in Texas, reflecting inconsistent access to evaluation services and underscoring the urgent need for standardized, accessible diagnostic approaches across all communities. 

“These new findings confirm what many healthcare providers and families have experienced firsthand – there is an urgent need for equitable access to early, objective autism diagnosis,” said Dr. Sharief Taraman, pediatric neurologist and CEO of Cognoa. “With research consistently showing better outcomes for children who receive timely support, we must work collectively to remove barriers to early identification.” 

Addressing Critical Diagnostic Delays
The current diagnostic pathway often requires families to wait months or even years to receive an autism evaluation from specialists. According to clinical data, the average time from initial concern to diagnosis remains approximately three years – a critical developmental window during which evidence-based interventions can have their greatest impact. 

Canvas Dx, developed by Cognoa, is the first FDA-authorized diagnostic aid that enables primary care clinicians to deliver an autism evaluation for children ages 18 months to 6 years, potentially reducing wait times from months to days. This technology supports healthcare providers in making more timely diagnostic decisions, helping families access appropriate support services much sooner. 

Collaborative Approach to Improving Access
Cognoa encourages multiple stakeholders to take action to help more children access timely diagnosis: 

For Healthcare Providers: 

  • Consider implementing objective diagnostic aids like Canvas Dx to supplement clinical judgment when evaluating children for developmental concerns
  • Discuss available diagnostic options with families who express developmental concerns 

For Health Insurers: 

  • Review coverage policies for FDA-authorized diagnostic aids for autism to ensure alignment with clinical best practices
  • Consider the downstream cost savings and improved outcomes associated with earlier intervention and support 

For Families: 

  • Discuss developmental concerns promptly with healthcare providers
  • Ask about available diagnostic approaches, including technology-enabled tools that may accelerate the evaluation process 

For Policymakers: 

  • Support initiatives that expand access to timely autism identification in underserved communities
  • Consider how Autism CARES Act funds might address diagnostic bottlenecks in the healthcare system 

“Early identification and appropriate support can significantly improve developmental trajectories for children on the autism spectrum,” said Dr. Taraman. “Several forward-thinking insurers and Medicaid programs have already recognized the value of covering tools like Canvas Dx, and we encourage others to join them in making early, accurate diagnosis accessible to all families.” 

About Cognoa
Cognoa is dedicated to transforming pediatric behavioral health through innovative, AI-powered solutions. Canvas Dx is the first FDA-authorized diagnostic aid enabling primary care clinicians to perform earlier, objective autism evaluations for children ages 18 months to 6 years. 

Contact: 
Emily Delong 
Emily.delong@cognoa.com 
+1 650-206-9273 

View original content:https://www.prnewswire.com/news-releases/cognoa-advocates-for-expanded-insurance-coverage-of-canvas-dx-as-cdc-reports-1-in-31-children-now-identified-with-autism-302431671.html

SOURCE Cognoa

Staff

Recent Posts

DIGITAL HEALTH LEADER JMIR PUBLICATIONS ANNOUNCES ITS 2025 IMPACT FACTOR RESULTS

The JMIR Publications portfolio of journals now includes 21 journals with a Journal Impact Factor, with…

4 hours ago

Integrated Theranostics Solutions and Bridge Oncology Launch Turnkey Theranostics Program to Help Fast-Track Radioligand Therapy Adoption

PADUCAH, Ky., June 20, 2025 /PRNewswire/ -- Integrated Theranostics Solutions (ITS) and Bridge Oncology today…

4 hours ago

Yale School of Medicine Launches Yale Biomedical Imaging Institute

NEW HAVEN, Conn., June 20, 2025 /PRNewswire/ -- Yale School of Medicine (YSM) announces the launch of…

4 hours ago

AI Tools That Talk, Scan, and Save Lives Are Reshaping the Investment Landscape

Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, June 20, 2025…

4 hours ago